Cim LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 6.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,807 shares of the company’s stock after purchasing an additional 556 shares during the quarter. Cim LLC’s holdings in Johnson & Johnson were worth $1,697,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its stake in Johnson & Johnson by 18.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after purchasing an additional 3,912,430 shares during the last quarter. FMR LLC lifted its position in shares of Johnson & Johnson by 20.8% in the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after buying an additional 3,229,032 shares during the last quarter. GQG Partners LLC boosted its stake in shares of Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of Johnson & Johnson by 52.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after acquiring an additional 2,093,392 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in Johnson & Johnson by 37.2% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock valued at $1,179,219,000 after acquiring an additional 1,805,632 shares during the period. Institutional investors own 67.94% of the company’s stock.
Analyst Upgrades and Downgrades
JNJ has been the topic of several research reports. SVB Leerink dropped their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Citigroup raised their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. StockNews.com began coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Credit Suisse Group initiated coverage on Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target for the company. Finally, Atlantic Securities decreased their price objective on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Wednesday, October 19th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $181.75.
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $168.31 on Wednesday. The stock has a market capitalization of $440.04 billion, a P/E ratio of 23.44, a PEG ratio of 3.21 and a beta of 0.56. The stock’s fifty day moving average is $175.98 and its 200 day moving average is $171.06. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.23 by $0.12. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. During the same period last year, the firm earned $2.13 EPS. The business’s quarterly revenue was down 4.4% compared to the same quarter last year. Sell-side analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 62.95%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.